XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 152 Months Ended
May 31, 2022
Apr. 30, 2022
Nov. 30, 2009
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Dec. 31, 2021
License agreements                  
Revenues       $ 911,397 $ 705,709 $ 1,644,632 $ 1,310,427    
Milestone and contract revenues                  
License agreements                  
Revenues       130,000 10,000 135,000 10,000    
Product royalty revenues                  
License agreements                  
Revenues       117,546 120,559 239,960 220,466    
JAKAFI                  
License agreements                  
Revenues       597,673 529,055 1,142,137 994,765    
Novartis                  
License agreements                  
Royalties payable       191,400   191,400   $ 191,400 $ 148,100
Novartis | Development Milestones                  
License agreements                  
Amount recognized and received for the achievement of a predefined milestone               157,000  
Novartis | Development Milestones | Maximum                  
License agreements                  
Upfront and immediate milestone payment to be received under license agreement     $ 174,000            
Novartis | Regulatory Milestones                  
License agreements                  
Amount recognized and received for the achievement of a predefined milestone               340,000  
Novartis | Regulatory Milestones | Maximum                  
License agreements                  
Upfront and immediate milestone payment to be received under license agreement     495,000            
Novartis | Commercialization Milestones                  
License agreements                  
Amount recognized and received for the achievement of a predefined milestone               $ 200,000  
Novartis | Commercialization Milestones | Maximum                  
License agreements                  
Upfront and immediate milestone payment to be received under license agreement     500,000            
Novartis | Development and Regulatory Milestones | Maximum                  
License agreements                  
Upfront and immediate milestone payment to be received under license agreement     $ 75,000            
Novartis | Milestone and contract revenues                  
License agreements                  
Revenues       60,000   60,000      
Novartis | JAKAVI                  
License agreements                  
Revenues       83,600 82,000 $ 154,600 147,600    
Novartis | JAKAVI | Minimum                  
License agreements                  
Royalty payments on future global net sales (as a percent)           12.00%      
Novartis | JAKAVI | Maximum                  
License agreements                  
Royalty payments on future global net sales (as a percent)           14.00%      
Novartis | JAKAVI | Regulatory Milestones                  
License agreements                  
Amount recognized and received for the achievement of a predefined milestone $ 45,000                
Novartis | TABRECTA                  
License agreements                  
Revenues       3,600 2,500 $ 7,100 4,500    
Novartis | TABRECTA | Regulatory Milestones                  
License agreements                  
Amount recognized and received for the achievement of a predefined milestone   $ 15,000              
Novartis | JAKAFI | U.S.                  
License agreements                  
Royalties payable on net sales       $ 29,300 $ 25,900 $ 51,000 $ 43,700